Protara Therapeutics, Inc. (NASDAQ:TARA) Stock Has Consensus Price Target of $26.25 According to Brokerages

Key Points

• Analyst sentiment is “Moderate Buy”: Seven of eight covering brokerages rate Protara Therapeutics a buy, while one recommends sell; the average 12-month price target is $26.25.
• Shares opened at $2.62, within a 52-week range of $2.09–$7.82, and below their 50-day and 200-day moving averages.
• Protara reported a quarterly loss of $0.35 per share, slightly better than analysts’ expected $0.37 loss. Analysts forecast a full-year loss of $1.38 per share.

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $26.25.

Several research analysts recently commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Cantor Fitzgerald reissued an "overweight" rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of Protara Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 5th.

Key Headlines Impacting Protara Therapeutics

These are some of the TARA headlines that stood out recently:

• Positive Sentiment: HC Wainwright raised its estimates for FY2026 EPS to a loss of $1.35 from $1.38, FY2027 to a loss of $1.37 from $1.50, and FY2028 to a loss of $0.41 from $0.43. It also improved its Q4 2026 estimate to a loss of $0.34 from $0.36. These less-negative projections may support sentiment, although they remain forecasts rather than reported results. HC Wainwright earnings estimate updates
• Neutral Sentiment: Short-interest reports are inconsistent: one says short interest fell 46.9% to about 3.24 million shares as of October 30, while another reports zero shares as of November 10. The conflicting figures make the near-term signal unclear. Protara short-interest reports
• Negative Sentiment: HC Wainwright trimmed its FY2030 EPS forecast slightly, to $1.08 from $1.09. The modest reduction is a negative revision to its longer-term outlook. HC Wainwright FY2030 estimate update

Institutional Trading of Protara Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Fisher Asset Management LLC boosted its position in shares of Protara Therapeutics by 30.2% in the 3rd quarter. Fisher Asset Management LLC now owns 129,612 shares of the company's stock worth $395,000 after purchasing an additional 30,046 shares in the last quarter. Alps Advisors Inc. increased its position in Protara Therapeutics by 36.3% during the 3rd quarter. Alps Advisors Inc. now owns 77,735 shares of the company's stock valued at $237,000 after buying an additional 20,694 shares in the last quarter. WINTON GROUP Ltd increased its position in Protara Therapeutics by 16.7% during the 2nd quarter. WINTON GROUP Ltd now owns 32,800 shares of the company's stock valued at $125,000 after buying an additional 4,700 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Protara Therapeutics during the 2nd quarter valued at about $69,000. Finally, Corient Private Wealth LP acquired a new position in Protara Therapeutics during the 2nd quarter valued at about $41,000. Hedge funds and other institutional investors own 38.13% of the company's stock.

Protara Therapeutics Stock Performance

Shares of Protara Therapeutics stock opened at $2.62 on Thursday. The company has a market capitalization of $161.31 million, a PE ratio of -1.88 and a beta of 1.54. The company has a 50-day simple moving average of $2.95 and a two-hundred day simple moving average of $4.44. Protara Therapeutics has a one year low of $2.09 and a one year high of $7.82.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.02. On average, equities analysts predict that Protara Therapeutics will post -1.38 earnings per share for the current fiscal year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company's lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer. Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.